دورية أكاديمية
Effects of MLC601 on early vascular events in patients after stroke: The CHIMES study
| العنوان: | Effects of MLC601 on early vascular events in patients after stroke: The CHIMES study |
|---|---|
| المؤلفون: | Pande, Shrikant, Tay, San San, Chan, Bernard P L, Mamauag, Marlie Jane, Young, Sherry H Y, Canete, Maria Teresa, Berame, Eli John, Chankrachang, Siwaporn, Chotickanuchit, Songkram, Suwanwela, Nijasri C., Towanabut, Somchai, Baroque, Alejandro C., Lokin, Johnny, Hiyadan, John Harold B, Sarfati, Ma Socorro, Fangonillo, Randolph John, Ambasing, Neil, Chua, Carlos L., San Jose, Ma Cristina, Muengtaweepongsa, Sombat, Poungvarin, Niphon, Luen, Teoh Hock, Sharma, Vijay, Advincula, Joel M., Eow, Gaik Bee, Wijekoon, Nirmala, Ranawake, Udaya, De Silva, H. Asita, Nitinun, Samart, De Silva, Deidre Anne, Chang, Hui Meng, Singh, Rajinder, Thirugnanam, Umapathi, Chen, Christopher L H, Venketasubramanian, Narayanaswamy, Lee, Chun Fan, Wong, K. S Lawrence, Bousser, Marie Germaine, Navarro, Jose C., Gan, Herminigildo H., Lao, Annabelle Y. |
| سنة النشر: | 2013 |
| المجموعة: | University of Hong Kong: HKU Scholars Hub |
| مصطلحات موضوعية: | Secondary prevention, Stroke, Vascular diseases, Clinical trial, Neuroaid |
| الوصف: | BACKGROUND AND PURPOSE - Early vascular events are an important cause of morbidity and mortality in the first 3 months after a stroke. We aimed to investigate the effects of MLC601 on the occurrence of early vascular events within 3 months of stroke onset. METHODS - Post hoc analysis was performed on data from subjects included in the CHInese Medicine Neuroaid Efficacy on Stroke recovery (CHIMES) study, a randomized, placebo-controlled, double-blinded trial that compared MLC601 with placebo in 1099 subjects with ischemic stroke of intermediate severity in the preceding 72 hours. Early vascular events were defined as a composite of recurrent stroke, acute coronary syndrome, and vascular death occurring within 3 months of stroke onset. RESULTS - The frequency of early vascular events during the 3-month follow-up was significantly less in the MLC601 group than in the placebo group (16 [2.9%] versus 31 events [5.6%]; risk difference=-2.7%; 95% confidence interval, -5.1% to -0.4%; P=0.025) without an increase in nonvascular deaths. Kaplan-Meier survival analysis showed a difference in the risk of vascular outcomes between the 2 groups as early as the first month after stroke (Log-rank P=0.024; hazard ratio, 0.51; 95% confidence interval, 0.28-0.93). CONCLUSIONS - Treatment with MLC601 was associated with reduced early vascular events among subjects in the CHIMES study. The mechanisms for this effect require further study. © 2013 American Heart Association, Inc. ; Link_to_subscribed_fulltext |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1524-4628 0039-2499 |
| العلاقة: | Stroke; Stroke, 2013, v. 44, n. 12, p. 3580-3583; 3583; 12; eid_2-s2.0-84889251989; 3580; http://hdl.handle.net/10722/220883Test; 44 |
| DOI: | 10.1161/STROKEAHA.113.003226 |
| الإتاحة: | https://doi.org/10.1161/STROKEAHA.113.003226Test http://hdl.handle.net/10722/220883Test |
| رقم الانضمام: | edsbas.E629B50A |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 15244628 00392499 |
|---|---|
| DOI: | 10.1161/STROKEAHA.113.003226 |